Table 4.
Summary of Selected Literature for High‐Sensitivity Troponin
| Study Authors | Populations Study Size | Change Units (Assay) | Outcomes | Adjusted Hazard Ratios |
|---|---|---|---|---|
| de Fillipi et al55 | Cardiovascular Health Study (mixed stable) (n=4221) | >12.94 pg/mL (hsTnT) | CV mortality | 2.91 (2.37 to 3.58) |
| de Lemos et al17 | Dallas Heart Study (mixed stable) (n=3546) | ≥0.0014 ηg/mL (hsTnT) | Mortality | 6.0 (4.7 to 11.3) |
| Omland et al41 | PEACE (stable CAD) (n=3679) | ≥0.0096 μg/L (men) ≥0.0074 μg/L (women) (hsTnT) |
CV mortality | 2.39 (1.85 to 3.09) (for hsTnT as a cont. variable) |
| Masson et al48 | Val‐HEFT GISSI‐HF (stable CHF for both) (n=5284) |
≥13.5 ηg/L for both (hsTnT) | Mortality for both | 1.60 (1.41 to 1.82) 1.97 (1.58 to 2.46) |
| Kavsak et al43 | HOPE (stable at risk for CAD/CHF) (n=2572) | ≥10 ηg/L (hs‐cTnI Beckman Coulter) | CV mortality | 2.2 (1.3 to 3.5) |
CAD indicates coronary artery disease; CHF, congestive heart failure; CV, cardiovascular; HsTnT, high‐sensitivity troponin T; Hs‐cTnI, high‐sensitivity cardiac troponin I.